EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

The Results of ADVANCE ‐ CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID /Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Mamatha Pasnoor, Colin Anderson-Smits, Todd Levine, Vera Bril iD, Juan Marcos Solano, Konrad Rejdak, Josep Gamez iD, Elisabeth Chroni iD, Carlos Casasnovas iD, Enrico Marchioni, Gabriele Siciliano, Dario Cocito und 11 weitere

European Journal of Neurology · 2025

DOI: 10.1111/ene.70110 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Mamatha Pasnoor und 22 weiteren Autor:innen. Beteiligte Einrichtung: University of Kansas Medical Center, Kansas City, Kansas, USA. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Immunoglobulins, Intravenous, Immunologic Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Development Center Americas, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ADVANCE‐CIDP IVIG evaluated the efficacy and safety of immune globulin infusion (human) 10% solution (IVIG 10%; GAMMAGARD LIQUID, also known as Kiovig) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) as a rescue treatment for patients relapsing during the ADVANCE‐CIDP 1 trial.

Methods

Open‐label ADVANCE‐CIDP IVIG included adult patients with confirmed CIDP relapse (≥ 1‐point increase in adjusted Inflammatory Neuropathy Cause and Treatment [INCAT] disability scores from pre‐treatment baseline) during ADVANCE‐CIDP 1, which assessed the efficacy and safety of hyaluronidase‐facilitated subcutaneous immunoglobulin (fSCIG) 10%. Patients received an induction IVIG 10% dose (2 g/kg) followed by maintenance infusions at the same monthly equivalent dose of pre‐randomization IVIG, 3‐weekly for 6 months. The primary outcome was the responder rate (≥ 1‐point decrease in adjusted INCAT scores at treatment cessation vs. pre‐IVIG 10% baseline, in patients receiving placebo in ADVANCE‐CIDP 1). Other outcomes included the responder rate across all patients relapsing on fSCIG 10% or placebo in ADVANCE‐CIDP 1, time to functional improvement (≥ 1‐point decrease in adjusted INCAT score), and change in adjusted INCAT scores and Rasch‐built Overall Disability Scale (R‐ODS) centile scores from pre‐IVIG 10% baseline.

Results

Overall, 20 patients received IVIG 10% ( n = 4 [fSCIG 10%‐relapse group]; n = 16 [placebo‐relapse group]). Responder rate (95% confidence interval) was 100.0% (80.6%–100.0%) in the placebo‐relapse group and 95.0% (76.4%–99.1%) in the overall‐relapse population. Across all patients, median time to functional improvement was 25 days. At treatment cessation, mean changes from pre‐IVIG 10% baseline in adjusted INCAT and R‐ODS centile scores were −1.9 and 12.9, respectively.

Conclusions

IVIG 10% effectively treated CIDP relapse and improved functional abilities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingImmunoglobulins, IntravenousImmunologic FactorsHumansMaleFemaleMiddle AgedAgedAdultTreatment OutcomeRecurrence

Stichwörter der Autor:innen

chronic inflammatory demyelinating polyradiculoneuropathyimmunoglobulin Gintravenous immunoglobulintreatment efficacy

Substanzen

Immunoglobulins, IntravenousImmunologic Factors

Autor:innen und Institutionen

  • University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
  • CND Life Sciences, Phoenix, Arizona, USA.
  • The Ellen and Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • IPS Universitaria and Neuromuscular Disorders Research Group, University of Antioquia, Medellín, Colombia.
  • Department of Neurology, Medical University of Lublin, Lublin, Poland.

ORCID-Profile: Vera Bril, Josep Gamez, Elisabeth Chroni, Carlos Casasnovas, Amir Dori, Hakan Ay

Förderung

  • Takeda Development Center Americas, Inc.

Zitieren

APA

Pasnoor, M., Anderson-Smits, C., Levine, T., Bril, V., Solano, J. M., Rejdak, K., Gamez, J., Chroni, E., Casasnovas, C., Marchioni, E., Siciliano, G., Cocito, D., Sivakumar, K., Rivero, A., Duff, K., Greco, E., Corbo, M., Hasan, S., Dori, A., …, & Ay, H. (2025). The Results of ADVANCE ‐ CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID /Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. European Journal of Neurology. https://doi.org/10.1111/ene.70110

Vancouver

Pasnoor M, Anderson-Smits C, Levine T, Bril V, Solano JM, Rejdak K, et al. The Results of ADVANCE ‐ CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID /Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. European Journal of Neurology. 2025. doi:10.1111/ene.70110

BibTeX
@article{Pasnoor2025,
  author = {Pasnoor, Mamatha and Anderson-Smits, Colin and Levine, Todd and Bril, Vera and Solano, Juan Marcos and Rejdak, Konrad and Gamez, Josep and Chroni, Elisabeth and Casasnovas, Carlos and Marchioni, Enrico and Siciliano, Gabriele and Cocito, Dario and Sivakumar, K and Rivero, Alberto and Duff, Kim and Greco, Erin and Corbo, Massimo and Hasan, Shabbir and Dori, Amir and Schmidt, Jens and Wood, Jamie and Li, Zhaoyang and Ay, Hakan},
  title = {The Results of ADVANCE ‐ CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID /Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70110}
}
Kostenlos starten →